ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Helix BioPharma Corp

Helix BioPharma Corp (HBP)

0,71
0,00
(0,00%)
Geschlossen 06 November 10:12PM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
0,71
Gebot
0,61
Fragen
0,99
Volumen
-
0,00 Tagesbereich 0,00
0,71 52-Wochen-Bereich 1,35
Marktkapitalisierung
Handelsende
0,71
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
4.976
Ausgegebene Aktien
49.022.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,76
Gewinn pro Aktie (EPS)
-0,19
Erlöse
-
Nettogewinn
-9,26M

Über Helix BioPharma Corp

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Toronto, Ontario, Can
Gegründet
-
Helix BioPharma Corp is listed in the Pharmaceutical Preparations sector of the Toronto Börse with ticker HBP. The last closing price for Helix BioPharma was $0,71. Over the last year, Helix BioPharma shares have traded in a share price range of $ 0,71 to $ 1,35.

Helix BioPharma currently has 49.022.000 shares in issue. The market capitalisation of Helix BioPharma is $34,81 million. Helix BioPharma has a price to earnings ratio (PE ratio) of -3.76.

HBP Neueste Nachrichten

Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results

RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...

Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results

RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary

RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in...

Proactive Virtual Event Showcases Four Rising Stars of the Life Sciences Industry

NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American...

Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum

RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results

RICHMOND HILL, Ontario, June 11, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

Helix BioPharma Corp. Provides Corporate Update

RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS

RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...

Helix BioPharma Corp. Closes $6.0 Million Private Placement

RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.19-21.11111111110.90.90.7130600.79013267CS
4-0.43-37.71929824561.141.340.7182841.05047051CS
12-0.39-35.45454545451.11.340.7149761.1400019CS
26-0.39-35.45454545451.11.350.7152121.14548529CS
52-0.54-43.21.251.350.71110331.07177008CS
156-1.99-73.70370370372.72.90.71133421.16847639CS
260-5.29-88.1666666667610.050.71173522.28956892CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
134AUPraise Inc
 0,00
(0,00%)
0
1332Nissui Corporation
 0,00
(0,00%)
0
132AIN Holdings Co Ltd
 0,00
(0,00%)
0
131ACCN Group Corp
 0,00
(0,00%)
0
130AVeritas In Silico Inc
 0,00
(0,00%)
0
134AUPraise Inc
 0,00
(0,00%)
0
1332Nissui Corporation
 0,00
(0,00%)
0
132AIN Holdings Co Ltd
 0,00
(0,00%)
0
131ACCN Group Corp
 0,00
(0,00%)
0
130AVeritas In Silico Inc
 0,00
(0,00%)
0
134AUPraise Inc
 0,00
(0,00%)
0
1332Nissui Corporation
 0,00
(0,00%)
0
132AIN Holdings Co Ltd
 0,00
(0,00%)
0
131ACCN Group Corp
 0,00
(0,00%)
0
130AVeritas In Silico Inc
 0,00
(0,00%)
0
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock